CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 8 enrolled
Drug / intervention
Regorafenibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02657551
NCT02657551Phase 2Active
CompareCT.gov

A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Dana-Farber Cancer Institute·interventional·Posted Jan 18, 2016·Updated Sep 11, 2025

In Brief

A Phase 2 clinical trial evaluating Regorafenib for Thyroid Cancer. Active but no longer recruiting, targeting 8 participants across 2 sites.

Detailed Summary

This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention involved in this study is regorafenib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
First PostedJan 18, 2016
Enrollment StartJan 1, 2016
Primary CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 10.5 years ago

Interventions

Regorafenibdrug

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.